<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038857</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-220</org_study_id>
    <nct_id>NCT00038857</nct_id>
  </id_info>
  <brief_title>Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases</brief_title>
  <official_title>Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Donor:

      This clinical study will evaluate the feasibility of a purified CD34 peripheral blood
      progenitor cell (PBPC) transplants in patients with hematological malignancies.

      The primary objectives of the study are to evaluate the recipient obtaining donor derived
      neutrophil engraftment and the incidence of acute graft versus host disease [GvHD] (grade
      III-IV).

      Secondary objectives include assessments of recipient having donor derived platelet
      engraftment, incidence of graft failure and chronic GvHD, overall and disease free survival,
      clinical safety and device performance of the CliniMACS CD34 selection device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Donor Description:

      Before taking part in this study, donors will have an evaluation that is the standard for any
      bone marrow or blood stem cell donor. These include standard blood tests, an
      electrocardiogram (EKG), and a chest X-ray. Donors will also be given a general health
      questionnaire that is given to all blood donors in the United States. It should take no more
      than 10 minutes to complete the questionnaire.

      Donors in this study will receive standard mobilization therapy with daily G-CSF every 12
      hours. The Granulocyte colony-stimulating factor (G-CSF) will be given as an injection under
      the skin. The mobilization phase starts on the first day that donors receive G-CSF and
      continues until the final day of the stem cell collection process (leukapheresis).

      Donors in this study will receive Neupogen (white blood cell growth factor) to stimulate the
      immature blood cells. They will receive two injections, twice a day for four days. On the
      fourth day, assuming they have enough immature white blood cells, researchers will start the
      stem cell collection process (leukapheresis).

      The stem cell collection will go from 1 to 4 days until enough immature cells have been
      collected, but will not be done on any day the donor's platelet count falls below 75,000. The
      stem cell is called a CD34(+) cell. These cells will then be processed over a cell-processing
      machine to try to purify the immature fraction of cells and remove the T-lymphocytes that are
      part of the fatal graft versus host disease. The T-cell is called a CD3(+) cell.

      Leukapheresis, with later CD34(+) cell selection, will start on the day when circulating
      CD34(+) count is at a high enough level. Leukapheresis will continue until the appropriate
      count is reached. If the CD3(+) count is too high, adjustments will be made.

      For those donors who cannot reach the collection goal in one series of collection attempts,
      researchers will wait until the donor recovers from the first stem cell collection and try
      again. If the donor is unable to reach the collection goal again, another attempt will be
      made with a different donor.

      The blood thinner used for the procedure will be acid citrate dextrose (ACD). Heparin may be
      substituted when clinically needed. No additional blood thinners or additives should be added
      beyond those normally used during leukapheresis. A unique identification and labeling system
      shall be used to track the leukapheresis product from collection to infusion.

      Samples will be taken from each leukapheresis product pre- and post-selection for quality
      analysis.

      This is an investigational study. No more than 90 donors will take part in this study. All
      will be enrolled at M. D. Anderson.

      Recipient Description:

      Before taking part in this study, recipients will have standard evaluations to determine the
      stage of their disease. These may include bone marrow aspirations and biopsies and if
      necessary, CT scans and chest x-rays. All recipients will go through cardiopulmonary
      evaluation.

      The recipients will have an allogeneic bone marrow transplant with pre-treatment of thiotepa,
      fludarabine, melphalan, and antithymocyte globulin. This will be followed by infusion of the
      peripheral blood progenitor cells.

      Recipients will have daily follow-up exams in the hospital. Recipients will be evaluated at
      least one to five times per week after they leave until Day 100. After that, they will have
      evaluations at least once every three months until about one year and then once every six
      months.

      The CliniMACS device is being provided by used of an investigational device exemption for the
      FDA. Without the CliniMACS device, this procedure would not be possible.

      This is an investigational study. A total of 40 patients will take part in this study. All
      will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Absolute Neutrophil Count Engraftment</measure>
    <time_frame>Day 0 up to Day 30</time_frame>
    <description>Absolute neutrophil engraftment defined as first of 3 consecutive days with Absolute neutrophil count (ANC) equal to or more than 0.5 * 10^9/L. Baseline to Day 30 post transplant.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD34 PBPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD34 peripheral blood progenitor cell (PBPC) transplants in 3 groups: 1) HLA-matched Sibling Transplant Patients; 2) Unrelated Donor Transplant Patients; 3) Haplo Identical Transplant Patients. Preparative regimen is 140 mg/m^2 Melphalan on day -8, 10 mg/kg Thiotepa on day -7, 160 mg/m^2 Fludarabine over 4 days on days -6, -5, -4, -3 and 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Megadose of CD34 Selected Progenitor Cells</intervention_name>
    <description>Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.</description>
    <arm_group_label>CD34 PBPC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>140 mg/m^2 on day -8</description>
    <arm_group_label>CD34 PBPC</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>10 mg/kg on day -7</description>
    <arm_group_label>CD34 PBPC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>160 mg/m^2 over 4 days on days -6, -5, -4, -3</description>
    <arm_group_label>CD34 PBPC</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit ATG</intervention_name>
    <description>1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.</description>
    <arm_group_label>CD34 PBPC</arm_group_label>
    <other_name>Rabbit antithymocyte globulin</other_name>
    <other_name>ATG</other_name>
    <other_name>rATG</other_name>
    <other_name>Genzyme</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female recipients must have histopathologically confirmed diagnosis of
             hematological or lymphatic malignancy in one of the following categories:

          2. Acute Leukemia: Recipients must have acute leukemia in second or greater remission in
             relapse, or primary refractory disease. Acute leukemia (in first remission with poor
             risk factors and molecular prognosis; acute myelogenous leukemia (AML) with -5, -7,
             t(6:9), +8, -11q23 and Acute lymphoblastic leukemia (ALL) with Phil+ t(9:22), t(4:11)
             and secondary remission inclusive).

          3. Chronic myelogenous leukemia: Chronic Myeloid Leukemia (CML) in accelerated phase,
             blast crisis or second chronic phase.

          4. Myelodysplastic syndrome (in high and intermediate risk categories) - marrow blast &gt;
             10% on differential.

          5. Non-Hodgkin's lymphoma in relapse

          6. Refractory chronic lymphoid leukemia (CLL) - refractory to fludarabine based regimen,
             unrelated donor and haploidentical only

          7. The recipient must be &lt;=60 years old at time of registration.

          8. The recipient must have a related donor haploidentical for human leukocyte antigen
             (HLA), A, B, C, or DR loci. They may be partial matched on the other haplotype.

          9. Recovery from prior therapy, chemotherapy, or radiotherapy, as defined by: Eastern
             Cooperative Oncology Group (ECOG) performance status equal or less than 2; have
             recovered from the toxicity of prior major chemotherapy at the start of the
             preparative regimen on this protocol

         10. Adequate cardiac and pulmonary function (Left ventricular ejection fraction (LVEF)
             &gt;45%, Carbon Monoxide Diffusing Capacity (DL CO)&gt;50% corrected for hemoglobin)

         11. Serum creatinine &lt;1.5 mg/dL or creatinine clearance &gt;50 ml/min for those above serum
             creatinine of 1.5; serum bilirubin &lt;2.0 mg/dL; Aspartate transaminase (AST)/alanine
             aminotransferase (ALT) &lt;2* Upper limits of normal (ULN) (unless secondary to disease)

         12. Females of childbearing potential must have a negative serum or urine beta-HCG test
             within three weeks of registration. Patients will be informed of the risk of not
             receiving adequate contraception.

         13. No prior cancer within five years with the exception of surgically cured non-melanoma
             skin cancer or in situ cancer of the cervix

         14. The recipient and/or the recipient's legal guardian must have been informed of the
             investigational nature of this study and have signed a consent form which is in
             accordance with Federal guidelines and the guidelines of the participating
             institution.

         15. Donor age must be 4-80 years and weight greater than 20 kg.

         16. Medical history and physical examination confirm good health status as defined by
             institutional standards

         17. Seronegative for HIV Ag, HIV 1+2 Ab, Human T Cell Leukemia Virus (HTLV) I/II Ab,
             HbsAg, HbcAb (IgM [combination screening test] and IgG), HCV, RPR for syphilis within
             30 days of apheresis collection - If positive for Hepatitis B or C or syphilis, the
             recipient must be notified - the recipient may proceed if PI, recipient and donor
             agree and there is no substitute donor

         18. HLA matching criteria

         19. Female donors of child-bearing potential must have a negative serum or urine beta-HCG
             test within three weeks of mobilization

         20. Capable of undergoing leukapheresis, have adequate venous access, and be willing to
             undergo insertion of a central catheter should leukapheresis via peripheral vein be
             inadequate

         21. Agreeable to second donation of PBPC (or a bone marrow harvest) should the patient
             fail to demonstrate sustained engraftment following the transplant

         22. The donor, or legal guardian greater than 18 years of age, must have been informed of
             the investigational nature of this study and have signed a consent form in accordance
             with Federal Guidelines and the guidelines of the participating institution. If the
             donor is less than 18 years of age, parent or legal guardian consent must be obtained.

         23. The prospective donor will be screened for cytomegalovirus (CMV) seroreactivity and a
             seronegative donor will be utilized if available when the patient is seronegative.

        Exclusion Criteria:

          1. Participation in other clinical trials which involve investigational drugs or devices
             that might influence the endpoints of this study

          2. Evidence of active hepatitis (B and/or C) or cirrhosis

          3. Neither the recipient nor the donor may be HIV positive

          4. Presence of any other active, uncontrolled bacterial, viral or fungal infection.

          5. Uncontrolled central nervous system (CNS) involvement with tumor cells

          6. Documented allergy to murine proteins or iron dextran

          7. The recipient is a lactating female or, if of child-bearing potential, is unwilling to
             implement adequate birth control.

          8. Severe end-organ dysfunctions, particularly neurologic deficits detectable by clinical
             examination or significant intellectual impairment in metabolic disorders

          9. Evidence of active infection (including urinary tract infection, or upper respiratory
             tract infection) or hepatitis (on screening).

         10. Medical or physical reason which makes the donor unlikely to tolerate or cooperate
             with growth factor therapy and leukapheresis.

         11. Factors that place the donor at increased risk for complications from leukapheresis or
             G-CSF therapy such as pulmonary hypertension, coronary artery disease, peripheral
             vascular disease, cerebral vascular disease.

         12. Lactating female or, if of child-bearing potential, is unwilling to implement adequate
             birth control.

         13. Donors who are hepatitis positive, Human T-cell lymphotropic virus type I (HTLVI)
             positive need consent of Principal Investigator and determination that this is the
             best donor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Champlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2002</study_first_submitted>
  <study_first_submitted_qc>June 6, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2002</study_first_posted>
  <results_first_submitted>June 21, 2012</results_first_submitted>
  <results_first_submitted_qc>June 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 7, 2012</results_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Acute Lymphocytic Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Non Hodgkin's Lymphoma</keyword>
  <keyword>T cell depletion</keyword>
  <keyword>CD34 selected progenitors cell</keyword>
  <keyword>GVHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period:October 1, 2001 to November 1, 2008. All participants recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 29 participants enrolled, one participant was excluded from the trial and did not receive any treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CD34 PBPC</title>
          <description>Melphalan 140 mg/m^2 given IV for one day. Thiotepa 10 mg/kg given IV for one day. Fludarabine 40 mg/m^2 given IV daily for four days. Rabbit ATG 1.5 mg/kg given IV daily for four days. Stem Cell Infusion of CD34+ Selected Cells given on Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CD34 PBPC</title>
          <description>Melphalan 140 mg/m^2 given IV for one day. Thiotepa 10 mg/kg given IV for one day. Fludarabine 40 mg/m^2 given IV daily for four days. Rabbit ATG 1.5 mg/kg given IV daily for four days. Stem Cell Infusion of CD34+ Selected Cells given on Day 0.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Absolute Neutrophil Count Engraftment</title>
        <description>Absolute neutrophil engraftment defined as first of 3 consecutive days with Absolute neutrophil count (ANC) equal to or more than 0.5 * 10^9/L. Baseline to Day 30 post transplant.</description>
        <time_frame>Day 0 up to Day 30</time_frame>
        <population>Analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Melphalan + Thiotepa + Fludarabine + Rabbit ATG + CD34 PBPC</title>
            <description>Melphalan 140 mg/m^2 given for one day. Thiotepa 10 mg/kg given for one day. Fludarabine 40 mg/m^2 given daily for four days. Rabbit ATG 1.5 mg/kg given daily for four days. Infusion of CD34+ Selected Cells given on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Absolute Neutrophil Count Engraftment</title>
          <description>Absolute neutrophil engraftment defined as first of 3 consecutive days with Absolute neutrophil count (ANC) equal to or more than 0.5 * 10^9/L. Baseline to Day 30 post transplant.</description>
          <population>Analysis per protocol.</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 Years, 1 Month (October 1, 2001 to November 1, 2008)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CD34 PBPC</title>
          <description>Melphalan 140 mg/m^2 given IV for one day. Thiotepa 10 mg/kg given IV for one day. Fludarabine 40 mg/m^2 given IV daily for four days. Rabbit ATG 1.5 mg/kg given IV daily for four days. Stem Cell Infusion of CD34+ Selected Cells given on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Thrombotic Microangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Graft Failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Disease Relapse</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Graft vs Host Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated alanine aminotransferase (ALT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Left Ureteral Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diffuse Alveolar Hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Graft versus Host Disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Elevated Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK Virus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Infecrtion</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard E. Champlin</name_or_title>
      <organization>MDAnderson Cancer Center</organization>
      <phone>713-792-8750</phone>
      <email>celsaenz@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

